iRadimed (NASDAQ:IRMD) Hits New 12-Month High – Still a Buy?

iRadimed Corporation (NASDAQ:IRMD)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $98.53 and last traded at $97.7850, with a volume of 5149 shares changing hands. The stock had previously closed at $97.45.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Lake Street Capital restated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.33.

iRadimed Stock Down 0.1%

The business has a 50-day simple moving average of $88.72 and a 200-day simple moving average of $74.34. The company has a market cap of $1.24 billion, a PE ratio of 58.97 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The business had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Insider Activity at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares in the company, valued at approximately $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $96.73, for a total value of $483,650.00. Following the completion of the transaction, the chief executive officer owned 2,287,500 shares in the company, valued at $221,269,875. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 65,000 shares of company stock valued at $5,548,150. 36.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On iRadimed

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after buying an additional 5,475 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of iRadimed by 6.5% during the 2nd quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after acquiring an additional 15,996 shares during the last quarter. Ranger Investment Management L.P. boosted its position in shares of iRadimed by 7.4% during the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock valued at $12,845,000 after acquiring an additional 14,730 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after purchasing an additional 1,821 shares during the period. Finally, Acadian Asset Management LLC increased its position in iRadimed by 10.9% during the first quarter. Acadian Asset Management LLC now owns 156,319 shares of the medical equipment provider’s stock worth $8,197,000 after purchasing an additional 15,329 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.